Navigation Links
QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
Date:4/10/2012

A feedback from the US Food and Drug Administration (FDA) in June 2012. QRxPharma's US partner for MoxDuo IR, Actavis, Inc has the option to negotiate for the US license of MoxDuo CR pending achievement of certain MoxDuo IR sales milestones in the acute pain market.

MoxDuo CR is expected to launch into the US chronic pain market in 2015.

OxyContin® and MS Contin® are registered trademarks of Purdue Pharma L.P.

About MoxDuo CR
MoxDuo CR is a patented 3:2 ratio fixed dose combination of morphine and oxycodone designed to relieve moderate to severe chronic pain as a once- to twice-a-day formulation. The MoxDuo CR formulation contains proprietary technology to limit tampering or abuse by inhalation or solubilisation in water or alcohol.

About QRxPharma
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. QRxPharma's lead product candidate, immediate release MoxDuo, has a Prescription Drug User Fee Act (PDUFA) date of 25 June 2012 when the New Drug Application review by the US Food and Drug Administration (FDA) will be completed. The Company recently signed a strategic partnership agreement with Actavis, Inc. to commercialise MoxDuo IR in the US acute pain market, with product launch anticipated in 3Q, CY2012. QRxPharma may co-promote its products in the US and plans to seek strategic partnerships for worldwide markets. Additionally, the Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo. For more information, vi
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... (NASDAQ: VOLC ), a global leader in catheter-based ... they have entered into a definitive merger agreement. Pursuant to ... all of the issued and outstanding shares of Volcano for ... of USD 1 billion (approx. EUR 800 million), to be ...
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... Light Sciences Oncology, Inc.,(LSO) today announced that it ... (BPH), or enlargement of the prostate, using Light,Infusion ... LSO plans to conduct a 12-patient, Phase I/II,dose-escalation ... as well as a,40-patient, Phase IIa study in ...
... Inc. (OTC,Bulletin Board: GOVX), an Atlanta based, ... and treatment of infectious,diseases, today provided an ... Phase 2 preventative human clinical trial testing ... with its AIDS vaccine. Five,successful human trials ...
Cached Medicine Technology:Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 2Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 3GeoVax Reports Progress on Its AIDS Vaccine Technology 2GeoVax Reports Progress on Its AIDS Vaccine Technology 3GeoVax Reports Progress on Its AIDS Vaccine Technology 4GeoVax Reports Progress on Its AIDS Vaccine Technology 5
(Date:12/19/2014)... December 19, 2014 The Hermitage ... club in Southern Vermont’s Deerfield Valley, announced today that ... by classic rock songs. , Three time Grammy ... a private concert followed by a trail naming ceremony. ... trail names include: “I’m Alright” the theme song for ...
(Date:12/19/2014)... The tragic death from "rat-bite fever" of a 10-year-old San ... according to a report from the U.S. Centers for Disease ... potentially fatal illness that should be considered in persons with ... rodent exposure is reported," said a team led by Dr. ... case outlined in the report occurred in August of 2013. ...
(Date:12/19/2014)... Traveling through the same U.S. airport gate, one infected ... a four-hour time span, illustrating just how easily the ... exposures in this report were not prolonged and occurred ... the fact that measles is highly contagious," wrote a ... at the U.S. Centers for Disease Control and Prevention. ...
(Date:12/17/2014)... While countless companies tempt patients to buy hCG ... of their purchase. Not only is the sale of hCG ... patients who buy hCG online are typically receiving products that ... real hCG present. Illegal internet hCG is typically manufactured outside ... and may contain unknown fillers that can pose very serious ...
(Date:12/17/2014)... Providence, RI (PRWEB) December 17, 2014 ... nationally recognize private practices that have made outstanding ... and in support and progression of private practice ... the American Physical Therapy Association. , On behalf ... DPT, OCS, owner and CEO of Performance accepted ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... InfoLogix,s e-Learning Team Develops Custom, Web-Based Training Solution ... Jan. 22 InfoLogix, Inc. (Nasdaq: ... of enterprise mobility and advanced wireless asset tracking ... today it has successfully deployed an advanced clinical ...
... and by male and female doctors, study finds , , ... heart failure is influenced by the gender of the ... evaluated 1,857 patients and the treatment records of 829 ... less likely to receive guideline-recommended medications, such as angiotensin-converting ...
... Clinic today announced the launch of its culture blog, Sharing Mayo ... and employees to share their stories about what makes Mayo Clinic ... ... -- Mayo Clinic today announced the launch of its culture blog, ...
... Initiatives, Inc. (Nasdaq: MTXX ), an over-the-counter ... consumers with "Better Ways to Get Better(R)," announced today ... ended December 31, 2008, will be released after the ... conference call will be held the following morning on ...
... a Difficult Target for Pharmaceutical Companies Wishing to Grow ... From Decision ResourcesWALTHAM, Mass., Jan. 22 /PRNewswire/ -- ... and advisory firms focusing on pharmaceutical and healthcare issues, ... ranks fourth in the number of untreated HIV patients ...
... Jan. 22 In 2008, The Larry King Cardiac,Foundation, ... individuals with no health insurance, increased the number of ... and continued to expand its,national network of partner hospitals. ... funds into individual medical procedures,the Foundation helped save the ...
Cached Medicine News:Health News:InfoLogix Develops Organizational Development and Mobility Training Solution for Edward Hospital 2Health News:InfoLogix Develops Organizational Development and Mobility Training Solution for Edward Hospital 3Health News:Gender May Influence Heart Failure Treatment 2Health News:Mayo Clinic Announces Sharing Mayo Clinic Blog for Patients, Employees 2Health News:Mayo Clinic Announces Sharing Mayo Clinic Blog for Patients, Employees 3Health News:Mayo Clinic Announces Sharing Mayo Clinic Blog for Patients, Employees 4Health News:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2009 Financial Results 2Health News:Georgia Ranks Fourth in the Number of Untreated HIV Patients in the United States 2Health News:Georgia Ranks Fourth in the Number of Untreated HIV Patients in the United States 3Health News:2008 a Year of Growth and Unprecedented Service for The Larry King Cardiac Foundation 2Health News:2008 a Year of Growth and Unprecedented Service for The Larry King Cardiac Foundation 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: